Drugs by condition
Drugs approved for chronic lymphocytic leukemia
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
32
Still marketed, NDA or BLA
Drug classes
8
Novel drugs
12
New molecular entities and new biologics
In development
17
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for chronic lymphocytic leukemia.
- Gobarden (Bendamustine Hydrochloride) · Avyxa Holdings Jul 3, 2025
- Brukinsa (Zanubrutinib) · Beone Medicines USA Accelerated approvalOrphanJun 10, 2025
- Cyclophosphamide (Cyclophosphamide) · Sandoz Sep 12, 2023
- Cyclophosphamide (Cyclophosphamide) · Baxter Hlthcare Corp Jun 27, 2023
- Frindovyx (Cyclophosphamide) · Avyxa Holdings Jun 7, 2023
All approved drugs for chronic lymphocytic leukemia, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 37 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Kinase Inhibitor (8)
- Jaypirca Pirtobrutinib · Loxo Oncol · 2023
- Calquence Acalabrutinib · Astrazeneca · 2017
- Zydelig Idelalisib · Gilead Sciences INC · 2014
- Imbruvica Ibrutinib · Pharmacyclics LLC · 2013
- Brukinsa Zanubrutinib · Beone Medicines USA · 2025
- Imbruvica Ibrutinib · Pharmacyclics LLC · 2022
- Calquence Acalabrutinib Maleate · Astrazeneca · 2022
- Imbruvica Ibrutinib · Pharmacyclics LLC · 2018
CD20-directed Cytolytic Antibody (5)
BCL-2 Inhibitor (1)
- Venclexta Venetoclax · Abbvie · 2016
Thalidomide Analog (1)
- Revlimid Lenalidomide · Bristol Myers Squibb · 2005
CD52-directed Cytolytic Antibody (1)
- Lemtrada Alemtuzumab · Genzyme · 2001
Alkylating Drug (1)
- Cyclophosphamide Cyclophosphamide · Dr Reddys · 2020
Endoglycosidase (1)
- Rituxan Hycela Rituximab, Hyaluronidase (Human Recombinant) · Genentech INC · 2017
Class not listed in FDA's data (14)
- Treanda Bendamustine Hydrochloride · Cephalon · 2008
- Thioguanine Thioguanine · Waylis Therap · 1966
- Cytoxan Cyclophosphamide · Baxter Hlthcare · 1959
- Gobarden Bendamustine Hydrochloride · Avyxa Holdings · 2025
- Cyclophosphamide Cyclophosphamide · Sandoz · 2023
- Cyclophosphamide Cyclophosphamide · Baxter Hlthcare Corp · 2023
- Frindovyx Cyclophosphamide · Avyxa Holdings · 2023
- Bendamustine Hydrochloride Bendamustine Hydrochloride · Baxter Hlthcare Corp · 2022
- Vivimusta Bendamustine Hydrochloride · Azurity · 2022
- Cyclophosphamide Cyclophosphamide · Eugia Pharma Speclts · 2021
- Copiktra Duvelisib · Secura · 2018
- Belrapzo Bendamustine Hydrochloride · Eagle Pharms · 2018
- Bendeka Bendamustine Hydrochloride · Eagle Pharms · 2015
- Cyclophosphamide Cyclophosphamide · Hikma · 2013
Drugs in development for chronic lymphocytic leukemia
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- APG-2575lisaftoclaxPhase 310 trials
Ascentage Pharma Group Inc. · CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials
Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia
- BirelentinibDZD8586Phase 37 trials
Dizal Pharmaceuticals · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immune Thrombocytopenia (ITP)
- NemtabrutinibMK-1026, ARQ 531Phase 36 trials
Merck & Co. · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
- RocbrutinibLP-168, NWP-775Phase 36 trials
Guangzhou Lupeng Pharmaceutical Company LTD. · Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma
- TacabrutidegBGB-16673Phase 36 trials
BeOne Medicines (BeiGene) · Chronic Lymphocytic Leukemia, B-cell Malignancy, Small Lymphocytic Lymphoma
- KRT-232NavtemadlinPhase 34 trials
Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- NX-5948bexobrutidegPhase 33 trials
Nurix Therapeutics, Inc. · B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- CLR 131I-131-CLR1404, Iopofosine I 131 single dosePhase 32 trials
Cellectar Biosciences, Inc. · Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia
- TQB3909Phase 32 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia, Myeloid Malignancy
- Zugocabtagene geleucelCTX112Phase 23 trials
CRISPR Therapeutics AG · B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy
- EmavusertibCA-4948Phase 22 trials
Curis, Inc. · Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma
- GNC-035Phase 22 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Relapsed/Refractory Chronic Lymphocytic Leukemia, Non-hodgkin's Lymphoma
- IDP-121Phase 22 trials
IDP Discovery Pharma S.L. · Small Cell Lung Cancer ( SCLC ), Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- LacutoclaxPhase 22 trials
Guangzhou Lupeng Pharmaceutical Company LTD. · Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL)
- ALLO-647Phase 21 trial
Allogene Therapeutics · Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
- MS-553Phase 21 trial
MingSight Pharmaceuticals, Inc · CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma)
1 discontinued brand-name drugs whose label still names it
- Brukinsa Zanubrutinib
More on chronic lymphocytic leukemia: recruiting trials · published research
Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelodysplastic syndromes · Myelofibrosis · Sickle cell disease · Hemophilia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.